메뉴 건너뛰기




Volumn 11, Issue , 2018, Pages 187-197

Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: A report on the emerging new data

Author keywords

Antidiabetic drugs; Diabetes mellitus; GLP 1 RA; Glucagon like peptide 1 receptor agonist; Incretin; Injectable

Indexed keywords

DULAGLUTIDE; EXENDIN 4; GLIMEPIRIDE; INSULIN LISPRO; LIXISENATIDE; METFORMIN; PIOGLITAZONE; SEMAGLUTIDE; SITAGLIPTIN; TASPOGLUTIDE;

EID: 85058526677     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S134960     Document Type: Review
Times cited : (19)

References (47)
  • 1
    • 79953065066 scopus 로고    scopus 로고
    • A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes
    • Barrington P, Chien JY, Showalter HDH, et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(5):426–433.
    • (2011) Diabetes Obes Metab , vol.13 , Issue.5 , pp. 426-433
    • Barrington, P.1    Chien, J.Y.2    Showalter, H.D.H.3
  • 3
    • 84969988486 scopus 로고    scopus 로고
    • Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: A comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
    • Jendle J, Grunberger G, Blevins T, Giorgino F, Hietpas RT, Botros FT. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev. 2016;32(8):776–790.
    • (2016) Diabetes Metab Res Rev , vol.32 , Issue.8 , pp. 776-790
    • Jendle, J.1    Grunberger, G.2    Blevins, T.3    Giorgino, F.4    Hietpas, R.T.5    Botros, F.T.6
  • 4
    • 84968867240 scopus 로고    scopus 로고
    • Advances in the treatment of type 2 diabetes: Impact of dulaglutide
    • Thompson AM, Trujillo JM. Advances in the treatment of type 2 diabetes: impact of dulaglutide. Diabetes Metab Syndr Obes. 2016;9:125–136.
    • (2016) Diabetes Metab Syndr Obes , vol.9 , pp. 125-136
    • Thompson, A.M.1    Trujillo, J.M.2
  • 5
    • 85014514372 scopus 로고    scopus 로고
    • Dulaglutide for the treatment of type 2 diabetes
    • Scheen AJ. Dulaglutide for the treatment of type 2 diabetes. Expert Opin Biol Ther. 2017;17(4):485–496.
    • (2017) Expert Opin Biol Ther , vol.17 , Issue.4 , pp. 485-496
    • Scheen, A.J.1
  • 6
    • 85050209004 scopus 로고    scopus 로고
    • Trulicity (dulaglutide) injection, solution [prescribing information] Indianapolis, IN: Eli Lilly and Company; 2017.
    • (2017) Eli Lilly and Company
  • 8
    • 84904360390 scopus 로고    scopus 로고
    • Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)
    • Umpierrez G, Tofe Povedano S, Perez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37(8):2168–2176.
    • (2014) Diabetes Care , vol.37 , Issue.8 , pp. 2168-2176
    • Umpierrez, G.1    Tofe Povedano, S.2    Perez Manghi, F.3    Shurzinske, L.4    Pechtner, V.5
  • 9
    • 84939565260 scopus 로고    scopus 로고
    • Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): A randomized, phase III study
    • Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab. 2015;17(9):849–858.
    • (2015) Diabetes Obes Metab , vol.17 , Issue.9 , pp. 849-858
    • Weinstock, R.S.1    Guerci, B.2    Umpierrez, G.3    Nauck, M.A.4    Skrivanek, Z.5    Milicevic, Z.6
  • 10
    • 84952014744 scopus 로고    scopus 로고
    • A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: An open-label, nonrandomized, phase 3 trial
    • Emoto M, Terauchi Y, Ozeki A, Oura T, Takeuchi M, Imaoka T. A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial. Endocr J. 2015;62(12):1101–1114.
    • (2015) Endocr J , vol.62 , Issue.12 , pp. 1101-1114
    • Emoto, M.1    Terauchi, Y.2    Ozeki, A.3    Oura, T.4    Takeuchi, M.5    Imaoka, T.6
  • 11
    • 84905012167 scopus 로고    scopus 로고
    • Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)
    • Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37(8):2159–2167.
    • (2014) Diabetes Care , vol.37 , Issue.8 , pp. 2159-2167
    • Wysham, C.1    Blevins, T.2    Arakaki, R.3
  • 12
    • 84908177336 scopus 로고    scopus 로고
    • Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): A randomised, open-label, phase 3, non-inferiority trial
    • Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384(9951):1349–1357.
    • (2014) Lancet , vol.384 , Issue.9951 , pp. 1349-1357
    • Dungan, K.M.1    Povedano, S.T.2    Forst, T.3
  • 13
    • 84957851776 scopus 로고    scopus 로고
    • Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study
    • Odawara M, Miyagawa J, Iwamoto N, Takita Y, Imaoka T, Takamura T. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study. Diabetes Obes Metab. 2016;18(3):249–257.
    • (2016) Diabetes Obes Metab , vol.18 , Issue.3 , pp. 249-257
    • Odawara, M.1    Miyagawa, J.2    Iwamoto, N.3    Takita, Y.4    Imaoka, T.5    Takamura, T.6
  • 14
    • 84962338740 scopus 로고    scopus 로고
    • Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2)
    • Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015;38(12):2241–2249.
    • (2015) Diabetes Care , vol.38 , Issue.12 , pp. 2241-2249
    • Giorgino, F.1    Benroubi, M.2    Sun, J.H.3    Zimmermann, A.G.4    Pechtner, V.5
  • 15
    • 84930074468 scopus 로고    scopus 로고
    • Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): A randomised, open-label, phase 3, non-inferiority study
    • Blonde L, Jendle J, Gross J, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet. 2015;385(9982):2057–2066.
    • (2015) Lancet , vol.385 , Issue.9982 , pp. 2057-2066
    • Blonde, L.1    Jendle, J.2    Gross, J.3
  • 16
    • 84942256934 scopus 로고    scopus 로고
    • Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: A randomized, open-label, phase III, non-inferiority study
    • Araki E, Inagaki N, Tanizawa Y, Oura T, Takeuchi M, Imaoka T. Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study. Diabetes Obes Metab. 2015;17(10):994–1002.
    • (2015) Diabetes Obes Metab , vol.17 , Issue.10 , pp. 994-1002
    • Araki, E.1    Inagaki, N.2    Tanizawa, Y.3    Oura, T.4    Takeuchi, M.5    Imaoka, T.6
  • 17
    • 85017656003 scopus 로고    scopus 로고
    • Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)
    • Pozzilli P, Norwood P, Jodar E, et al. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). Diabetes Obes Metab. 2017;19(7):1024–1031.
    • (2017) Diabetes Obes Metab , vol.19 , Issue.7 , pp. 1024-1031
    • Pozzilli, P.1    Norwood, P.2    Jodar, E.3
  • 18
    • 84975720736 scopus 로고    scopus 로고
    • A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8)
    • Dungan KM, Weitgasser R, Perez Manghi F, et al. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8). Diabetes Obes Metab. 2016;18(5):475–482.
    • (2016) Diabetes Obes Metab , vol.18 , Issue.5 , pp. 475-482
    • Dungan, K.M.1    Weitgasser, R.2    Perez Manghi, F.3
  • 19
    • 85019155331 scopus 로고    scopus 로고
    • Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials
    • Monami M, Zannoni S, Pala L, et al. Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. Int J Cardiol. 2017;240:414–421.
    • (2017) Int J Cardiol , vol.240 , pp. 414-421
    • Monami, M.1    Zannoni, S.2    Pala, L.3
  • 20
    • 84959155948 scopus 로고    scopus 로고
    • Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: A pre-specified meta-analysis of prospectively adjudicated cardiovascular events
    • Ferdinand KC, Botros FT, Atisso CM, Sager PT. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol. 2016;15(1):38.
    • (2016) Cardiovasc Diabetol , vol.15 , Issue.1 , pp. 38
    • Ferdinand, K.C.1    Botros, F.T.2    Atisso, C.M.3    Sager, P.T.4
  • 21
    • 85046561203 scopus 로고    scopus 로고
    • Bethesda, MD: National Library of Medicine; 2011–2013: clinicaltrials.gov. NLM Identifier: NCT01394952. Accessed March 22
    • Eli Lilly and Company. Researching cardiovascular events with a weekly incretin in diabetes (REWIND). Bethesda, MD: National Library of Medicine; 2011–2013. Available from: clinicaltrials.gov. NLM Identifier: NCT01394952. Accessed March 22, 2018.
    • (2018) Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND).
  • 22
    • 84943197778 scopus 로고    scopus 로고
    • Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
    • Sun F, Wu S, Guo S, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110(1):26–37.
    • (2015) Diabetes Res Clin Pract , vol.110 , Issue.1 , pp. 26-37
    • Sun, F.1    Wu, S.2    Guo, S.3
  • 23
    • 84914666192 scopus 로고    scopus 로고
    • Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus
    • Ferdinand KC, White WB, Calhoun DA, et al. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014;64(4):731–737.
    • (2014) Hypertension , vol.64 , Issue.4 , pp. 731-737
    • Ferdinand, K.C.1    White, W.B.2    Calhoun, D.A.3
  • 24
    • 85014807800 scopus 로고    scopus 로고
    • Efficacy and safety of dulaglutide in Hispanic/Latino patients with type 2 diabetes in the AWARD clinical program
    • Davidson JA, Manghi FP, Yu M, Linetzky B, Lando LF. Efficacy and safety of dulaglutide in Hispanic/Latino patients with type 2 diabetes in the AWARD clinical program. Endocr Pract. 2016;22(12):1406–1414.
    • (2016) Endocr Pract , vol.22 , Issue.12 , pp. 1406-1414
    • Davidson, J.A.1    Manghi, F.P.2    Yu, M.3    Linetzky, B.4    Lando, L.F.5
  • 25
    • 85018340448 scopus 로고    scopus 로고
    • Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment
    • Hamano K, Nishiyama H, Matsui A, Sato M, Takeuchi M. Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment. Endocr J. 2017;64(4):449–456.
    • (2017) Endocr J , vol.64 , Issue.4 , pp. 449-456
    • Hamano, K.1    Nishiyama, H.2    Matsui, A.3    Sato, M.4    Takeuchi, M.5
  • 26
    • 85020089476 scopus 로고    scopus 로고
    • Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan
    • Onishi Y, Oura T, Matsui A, Matsuura J, Iwamoto N. Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan. Endocr J. 2017;64(5):553–560.
    • (2017) Endocr J , vol.64 , Issue.5 , pp. 553-560
    • Onishi, Y.1    Oura, T.2    Matsui, A.3    Matsuura, J.4    Iwamoto, N.5
  • 27
    • 84953898275 scopus 로고    scopus 로고
    • Efficacy and safety of dulaglutide in patients with type 2 diabetes: A meta-analysis and systematic review
    • Zhang L, Zhang M, Zhang Y, Tong N. Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review. Sci Rep. 2016;6:18904.
    • (2016) Sci Rep , vol.6
    • Zhang, L.1    Zhang, M.2    Zhang, Y.3    Tong, N.4
  • 28
    • 84962028683 scopus 로고    scopus 로고
    • Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes
    • Onishi Y, Oura T, Nishiyama H, Ohyama S, Takeuchi M, Iwamoto N. Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes. Endocr J. 2016;63(3):263–273.
    • (2016) Endocr J , vol.63 , Issue.3 , pp. 263-273
    • Onishi, Y.1    Oura, T.2    Nishiyama, H.3    Ohyama, S.4    Takeuchi, M.5    Iwamoto, N.6
  • 29
    • 84955304504 scopus 로고    scopus 로고
    • Benefits and harms of once-weekly glucagon-like peptide-1 receptor agonist treatments: A systematic review and network meta-analysis
    • Zaccardi F, Htike ZZ, Webb DR, Khunti K, Davies MJ. Benefits and harms of once-weekly glucagon-like peptide-1 receptor agonist treatments: a systematic review and network meta-analysis. Ann Intern Med. 2016;164(2):102–113.
    • (2016) Ann Intern Med , vol.164 , Issue.2 , pp. 102-113
    • Zaccardi, F.1    Htike, Z.Z.2    Webb, D.R.3    Khunti, K.4    Davies, M.J.5
  • 30
    • 85019350081 scopus 로고    scopus 로고
    • Assessment of pancreas safety in the development program of once-weekly GLP-1 receptor agonist dulaglutide
    • Nauck MA, Frossard JL, Barkin JS, et al. Assessment of pancreas safety in the development program of once-weekly GLP-1 receptor agonist dulaglutide. Diabetes Care. 2017;40(5):647–654.
    • (2017) Diabetes Care , vol.40 , Issue.5 , pp. 647-654
    • Nauck, M.A.1    Frossard, J.L.2    Barkin, J.S.3
  • 31
    • 85014039439 scopus 로고    scopus 로고
    • Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials
    • Emoto M, Oura T, Matsui A, Kazama H, Iwamoto N. Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials. Endocr J. 2017;64(2): 191–206.
    • (2017) Endocr J , vol.64 , Issue.2 , pp. 191-206
    • Emoto, M.1    Oura, T.2    Matsui, A.3    Kazama, H.4    Iwamoto, N.5
  • 32
    • 84961174431 scopus 로고    scopus 로고
    • Tumour risk with once-weekly glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review
    • Guo X, Yang Q, Dong J, Liao L, Zhang W, Liu F. Tumour risk with once-weekly glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: a systematic review. Clin Drug Investig. 2016;36(6):433–441.
    • (2016) Clin Drug Investig , vol.36 , Issue.6 , pp. 433-441
    • Guo, X.1    Yang, Q.2    Dong, J.3    Liao, L.4    Zhang, W.5    Liu, F.6
  • 33
    • 85007008175 scopus 로고    scopus 로고
    • Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials
    • Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab. 2017;19(3):336–347.
    • (2017) Diabetes Obes Metab , vol.19 , Issue.3 , pp. 336-347
    • Bettge, K.1    Kahle, M.2    Abd El Aziz, M.S.3    Meier, J.J.4    Nauck, M.A.5
  • 34
    • 85026922718 scopus 로고    scopus 로고
    • Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A meta-analysis of randomized controlled trials
    • Dicembrini I, Nreu B, Scatena A, et al. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2017;54(10):933–941.
    • (2017) Acta Diabetol , vol.54 , Issue.10 , pp. 933-941
    • Dicembrini, I.1    Nreu, B.2    Scatena, A.3
  • 35
    • 85038423099 scopus 로고    scopus 로고
    • Liraglutide and renal outcomes in type 2 diabetes
    • Mann JFE, Orsted DD, Buse JB. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(22):2197–2198.
    • (2017) N Engl J Med , vol.377 , Issue.22 , pp. 2197-2198
    • Mann, J.F.E.1    Orsted, D.D.2    Buse, J.B.3
  • 36
    • 84958767889 scopus 로고    scopus 로고
    • Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide
    • Grunberger G, Forst T, Fernandez Lando L, et al. Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide. Diabet Med. 2016;33(3):391–394.
    • (2016) Diabet Med , vol.33 , Issue.3 , pp. 391-394
    • Grunberger, G.1    Forst, T.2    Fernandez Lando, L.3
  • 37
    • 84979285154 scopus 로고    scopus 로고
    • Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes
    • Wysham C, Guerci B, D’Alessio D, Jia N, Botros FT. Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18(11): 1138–1142.
    • (2016) Diabetes Obes Metab , vol.18 , Issue.11 , pp. 1138-1142
    • Wysham, C.1    Guerci, B.2    D’Alessio, D.3    Jia, N.4    Botros, F.T.5
  • 38
    • 84939478562 scopus 로고    scopus 로고
    • Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: Data from the AWARD-1 and AWARD-3 clinical trials
    • Reaney M, Yu M, Lakshmanan M, Pechtner V, van Brunt K. Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes Obes Metab. 2015;17(9):896–903.
    • (2015) Diabetes Obes Metab , vol.17 , Issue.9 , pp. 896-903
    • Reaney, M.1    Yu, M.2    Lakshmanan, M.3    Pechtner, V.4    van Brunt, K.5
  • 39
    • 84959871701 scopus 로고    scopus 로고
    • Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: Data from the AWARD phase III clinical trial programme
    • Yu M, Van Brunt K, Varnado OJ, Boye KS. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes Obes Metab. 2016;18(4):419–424.
    • (2016) Diabetes Obes Metab , vol.18 , Issue.4 , pp. 419-424
    • Yu, M.1    van Brunt, K.2    Varnado, O.J.3    Boye, K.S.4
  • 40
    • 85020393265 scopus 로고    scopus 로고
    • Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: Comparisons with liraglutide, insulin glargine, and placebo in two randomized studies
    • Suzuki S, Oura T, Takeuchi M, Boye KS. Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies. Health Qual Life Outcomes. 2017;15(1):123.
    • (2017) Health Qual Life Outcomes , vol.15 , Issue.1 , pp. 123
    • Suzuki, S.1    Oura, T.2    Takeuchi, M.3    Boye, K.S.4
  • 41
    • 85039705599 scopus 로고    scopus 로고
    • Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes – 2018
    • American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes – 2018. Diabetes Care. 2018;41(suppl 1):S73–S85.
    • (2018) Diabetes Care. , vol.41 , pp. S73-S85
  • 42
    • 84978839381 scopus 로고    scopus 로고
    • Liraglutide and cardiovascular outcomes in type 2 diabetes
    • Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
    • (2016) N Engl J Med , vol.375 , Issue.4 , pp. 311-322
    • Marso, S.P.1    Daniels, G.H.2    Brown-Frandsen, K.3
  • 43
    • 84994813253 scopus 로고    scopus 로고
    • Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
    • Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19): 1834–1844.
    • (2016) N Engl J Med , vol.375 , Issue.19 , pp. 1834-1844
    • Marso, S.P.1    Bain, S.C.2    Consoli, A.3
  • 44
    • 85030448557 scopus 로고    scopus 로고
    • Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
    • Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13): 1228–1239.
    • (2017) N Engl J Med , vol.377 , Issue.13 , pp. 1228-1239
    • Holman, R.R.1    Bethel, M.A.2    Mentz, R.J.3
  • 45
    • 84944800184 scopus 로고    scopus 로고
    • Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
    • Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22): 2117–2128.
    • (2015) N Engl J Med , vol.373 , Issue.22 , pp. 2117-2128
    • Zinman, B.1    Wanner, C.2    Lachin, J.M.3
  • 46
    • 85034774651 scopus 로고    scopus 로고
    • Canagliflozin and cardiovascular and renal events in type 2 diabetes
    • Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(21):644–657.
    • (2017) N Engl J Med , vol.377 , Issue.21 , pp. 644-657
    • Neal, B.1    Perkovic, V.2    Matthews, D.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.